Logo

Epigenomics Closes 21M Series C Round

Apr 03, 2003

NEW YORK, April 3 - Epigenomics has closed a Series C round of financing worth €21 million, or around $ 22.5 million, the company said today.

 

This third round brings to €56 million the total capital raised by the DNA methylation firm since it was created in 1998. Epigenomics said it will use the funds to further develop its diagnostic products in cancer, as well as its pharmacodiagnostic and research products.

 

New investor the Wellcome Trust Limited and all existing VC investors--3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital, and tbg--participated in the round.

Breaking News
The Scan

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to an aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.